ARS-1620 is primarily used in cancer research, particularly in the study of KRAS-mutant cancers. It serves as a potent and selective inhibitor of the KRAS G12C mutation, which is commonly found in various types of cancers, including lung, colorectal, and pancreatic cancers. By targeting this specific mutation, ARS-1620 helps researchers understand the mechanisms of KRAS-driven tumorigenesis and evaluate potential therapeutic strategies. Its application in preclinical studies has been crucial for developing targeted therapies that aim to inhibit the growth and survival of cancer cells harboring the KRAS G12C mutation. Additionally, ARS-1620 is used to assess the efficacy of combination therapies, where it is paired with other anticancer agents to enhance treatment outcomes. This compound has become a valuable tool in advancing precision medicine approaches for treating KRAS-mutant cancers.